FLX Bio Picks Up $60M
South San Francisco-based FLX Bio, a biopharmaceuticals developer which is developing oral small-molecule drugs to activate the immune system against cancer, has raised $60M in a Series C funding. The funding came from GV (formerly Google Ventures), The Column Group, Kleiner Perkins, Topspin Partners and Celgene Corporation. Brian Wong, M.D., Ph.D. is President and CEO of FLX Bio.
posted on Thursday, December 21, 2017
Related companies:
FLX Bio, Inc.
Related stories:
> Zimride Picks Up $6M
> SmartRecruiters Picks Up $30M For Recruiting Tools
> PerimeterX Picks Up $23M More
> Pat Picks Up $2.5M For AI Software
> Nlyte Gets $12M
silicontap.com Home